乳腺癌是全身性疾病，大约有40%左右的乳腺癌病人在接受系统性的治疗后仍会出现复发转移，其
结局大部分因转移而死亡，以晚期乳腺癌病人居多。而多数病人已对传统的蒽环、紫杉醇类药物耐药。近年来，
针对晚期乳腺癌的治疗已逐渐达成共识，在保证病人生存时间及疗效的基础上，挑选毒副反应少安全性好的药
物，在最大程度上提高病人生存质量已成为治疗原则。因此，卡培他滨以其良好的疗效及轻微的副反应逐渐在
临床应用中显示出自己的优越性。本文主要阐述卡培他滨对于晚期乳腺癌的疗效和安全性等方面做相关讨论。

Breast cancer is a systemic disease，about 40%of the treatment of breast cancer patients
undergoing systemic recurrence after still there will be a transfer， the end most of the deaths due to
transfer， in the majority with advanced breast cancer patients．Most patients have been resistant to the
traditional anthracene， taxol．In recent years， for the treatment of advanced breast cancer has been gradually
reached a consensus，on the basis of ensure the curative effect and survival time，choose good drug
safety， little adverse reaction in the largest extent， improve the quality of survival has become a therapeutic
principles．Thus， the superior efficacy and mild side effects of capecitabine in clinical treatment
are increasingly evident in clinical treatment．This paper mainly discusses the efficacy and safety of the
treatment of advanced breast cancer．

Ｒ605